<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452398</url>
  </required_header>
  <id_info>
    <org_study_id>CS0115</org_study_id>
    <nct_id>NCT02452398</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Hair Removal and Permanent Hair Reduction for Skin Types VI Using Intense Pulsed Light</brief_title>
  <official_title>Clinical Evaluation of Hair Removal and Permanent Hair Reduction for Skin Types V-VI Using Intense Pulsed Light</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Venus Concept</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Venus Concept</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Multi-center, blinded, baseline-controlled, prospective study to evaluate permanent&#xD;
      hair reduction and removal for skin types V and VI using IPL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One hundred and twenty (120) subjects who are Fitzpatrick Skin Type V-VI, and have a suitable&#xD;
      treatment area for hair removal will be evaluated in this study.&#xD;
&#xD;
      Each subject will receive six treatments at four to six week intervals upon re-growth of hair&#xD;
      and return for follow-up visits at one, three and six months after the last treatment.&#xD;
&#xD;
      Measurement Equipment Standard High Resolution Digital Camera&#xD;
&#xD;
      Labels for hair count Customized hair count sticker templates will be placed directly on the&#xD;
      skin and the hairs in this window will be counted at specific visits during the study as&#xD;
      detailed in section.&#xD;
&#xD;
      Study Procedures Each subject will participate in the study for a period of at least 11&#xD;
      months. The study is anticipated to be completed within twelve months.&#xD;
&#xD;
      Test spots Up to 3 test spots will be performed in the selected treatment area to determine&#xD;
      the optimal parameters / setting.&#xD;
&#xD;
      Treatment&#xD;
&#xD;
      The treatment areas are divided into 3 groups. Each Subjects will be allocated to one of the&#xD;
      following groups::&#xD;
&#xD;
        -  Two small anatomical areas (right and left axillae and double sided bikini line) or;&#xD;
&#xD;
        -  One double sided large area (right and left thighs) or;&#xD;
&#xD;
        -  One large area (whole back / abdomen)&#xD;
&#xD;
      Based on the mild nature of treatment, anesthesia is not required. Before starting treatment&#xD;
      apply a layer of conductive gel to the treatment area.&#xD;
&#xD;
      After applying the conductive gel, locate the applicator in close contact, perpendicular to&#xD;
      the skin with no pressure applied. Pressing the applicator will fire the IPL pulse. In order&#xD;
      to ensure full coverage of the treatment area applicator placement should overlap&#xD;
      approximately 1/3 of the previously treated skin.&#xD;
&#xD;
      Post-treatment Instructions Cold packs may be placed on the treated area for post treatment&#xD;
      cooling. Subjects should be aware that post treatment erythema, edema and some discomfort of&#xD;
      the treated areas are possible and should not be a cause for concern. They may also&#xD;
      experience some purpura in the treated areas which would be expected to resolve within&#xD;
      several days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study withdrawn as technology already proven with data no longer needed.&#xD;
  </why_stopped>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">April 18, 2017</completion_date>
  <primary_completion_date type="Actual">March 27, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hair Count 6 Months Following Last Treatment</measure>
    <time_frame>6 months after last treatment</time_frame>
    <description>Hair count reduction in marked treatment area assessed from photographs taken 6 months following the last treatment as compared to photographs of the marked treatment area taken at baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Removal of Excess or Unwanted Body Hair</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hair removal treatment using Venus Versa IPL energy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject hair count at baseline will act as the control to which the hair count at 6 months after the last treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment group</intervention_name>
    <description>The intense pulsed light (IPL) applicator with a wavelength of 690 nm and spot size (treatment area) of 30 mm by 10 mm will be used to deliver the energy to the treatment area.</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Subject will act as their own control where the baseline hair count will be used as a comparator to the hair count after treatment.</description>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to read, understand and provide written Informed Consent;&#xD;
&#xD;
          2. Subject has black or dark brown terminal hairs in the areas to be treated.&#xD;
&#xD;
          3. Terminal hair density requirement of greater than 15 hairs within the hair count site&#xD;
             (3x3 cm area) as determined by manual hair count performed by the study investigator.&#xD;
&#xD;
          4. Healthy adult, male or female, 21 years of age or older with skin type V-VI;&#xD;
&#xD;
          5. Having a suitable treatment area for hair removal;&#xD;
&#xD;
          6. Able and willing to comply with the treatment/follow-up schedule and requirements;&#xD;
&#xD;
          7. Women of child-bearing potential (women who have not had a hysterectomy, bilateral&#xD;
             oophorectomy or are not postmenopausal) are required to be using a reliable method of&#xD;
             birth control at least three months prior to enrollment and throughout the course of&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has light ,gray terminal or fine hairs in all/some parts of the treated area;&#xD;
&#xD;
          2. Pregnant, expectation of pregnancy, postpartum or nursing (&lt;6 months);&#xD;
&#xD;
          3. Hormonal disorders that may affect hair growth;&#xD;
&#xD;
          4. Immunosuppressive diseases, including AIDS and HIV infection, or use of&#xD;
             immunosuppressive medications;&#xD;
&#xD;
          5. Livedo reticularis;&#xD;
&#xD;
          6. Uncontrolled systemic diseases such as diabetes;&#xD;
&#xD;
          7. Active infections in the treated area;&#xD;
&#xD;
          8. Dysplastic nevi;&#xD;
&#xD;
          9. Significant concurrent skin conditions or any inflammatory skin conditions;&#xD;
&#xD;
         10. Active cold sores, open lacerations or abrasions;&#xD;
&#xD;
         11. Chronic or cutaneous viral, fungal, or bacterial diseases;&#xD;
&#xD;
         12. Current cancer;&#xD;
&#xD;
         13. History of skin cancer or pre-cancerous lesions at the treatment areas;&#xD;
&#xD;
         14. Use of Accutaneâ„¢ (Isotretinoin) within the past six month;&#xD;
&#xD;
         15. Keloid or Hypertrophic scar formation in the treatment area;&#xD;
&#xD;
         16. Tattoos in the treatment area;&#xD;
&#xD;
         17. Bleeding coagulopathies or use of anticoagulants;&#xD;
&#xD;
         18. Auto-immune disorders;&#xD;
&#xD;
         19. Erythema abigne, when identified treatments should be discontinued;&#xD;
&#xD;
         20. Photosensitivity disorder that can be exacerbated by laser or intense light;&#xD;
&#xD;
         21. Herpes simplex in the treatment area;&#xD;
&#xD;
         22. Use of medications, herbal supplements, perfumes or cosmetics that may affect&#xD;
             sensitivity to light;&#xD;
&#xD;
         23. Poor wound healing;&#xD;
&#xD;
         24. Sunburns;&#xD;
&#xD;
         25. Unable or unlikely to refrain from artificial tanning, including the use of tanning&#xD;
             booths, prior (at least a month) and during the course of the evaluation;&#xD;
&#xD;
         26. Prior skin treatment with laser or other devices on the same treated areas within the&#xD;
             last six months prior to study enrollment or during the course of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracey L Mancuso</last_name>
    <role>Study Director</role>
    <affiliation>Venus Concept</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology and Laser Centre</name>
      <address>
        <city>Manhattan Beach</city>
        <state>California</state>
        <zip>90266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 8, 2015</study_first_submitted>
  <study_first_submitted_qc>May 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <results_first_submitted>April 9, 2018</results_first_submitted>
  <results_first_submitted_qc>October 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 3, 2020</results_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hair removal</keyword>
  <keyword>depilation</keyword>
  <keyword>epilation</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 3, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02452398/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was terminated and no results analysis was done.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>Hair removal treatment using Venus Versa IPL energy&#xD;
Venus Versa: The Venus Versa system is a multi-application device intended to be used in aesthetic and cosmetic procedures.&#xD;
The device consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated. The applicator that will be used for this study (HR 690) has a wavelength of 690 nm and has a spot size (treatment area) of 30 mm by 10 mm.&#xD;
IPL gel: water based gel used to protect the skin during light based treatments. Also used during ultrasound treatments.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79">Study was halted prematurely. No results analysis completed.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38">Study was halted prematurely. No results analysis completed.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved away</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data were not collected.</population>
      <group_list>
        <group group_id="B1">
          <title>Hair Removal With Versa HR 690nm Applicator</title>
          <description>Subjects with Fitzpatrick skin type V-VI requesting hair removal (right and left axillae and double sided bikini line) or one double sided large area (right and left thighs) or one large area (whole back / abdomen).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hair count in marked treatment area</title>
          <population>Data were not collected.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hair Count 6 Months Following Last Treatment</title>
        <description>Hair count reduction in marked treatment area assessed from photographs taken 6 months following the last treatment as compared to photographs of the marked treatment area taken at baseline.</description>
        <time_frame>6 months after last treatment</time_frame>
        <population>This primary outcome measurement could not be reported as data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Enrolled subjects acted as their own control. Each received Venus Versa IPL treatment to remove hair in marked treatment area.</description>
          </group>
        </group_list>
        <measure>
          <title>Hair Count 6 Months Following Last Treatment</title>
          <description>Hair count reduction in marked treatment area assessed from photographs taken 6 months following the last treatment as compared to photographs of the marked treatment area taken at baseline.</description>
          <population>This primary outcome measurement could not be reported as data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse event data was collected over a period of 2 years and 2 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hair Removal With Versa HR 690nm Applicator</title>
          <description>All subjects who received at least one hair removal treatment with the Versa HR 690 nm applicator.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated due to slow recruitment (over 2 years and the target enrollment had not been reached).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Yoni Iger</name_or_title>
      <organization>Venus Concept Ltd</organization>
      <phone>888-907-0115</phone>
      <email>yoni@venusconcept.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

